Advanced Practice Providers

A care model led by advanced practice nurses was feasible in providing supportive care and linking providers through post-trial care transitions.

Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary investigators.

Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.

Nurse practitioners should listen to patients’ concerns and be ready with questions when it comes to germline testing, according to an expert.

Using risk assessment and nurse education in the High ED/Admission Risk Therapy (HEART) protocol reduced ED visits by 18% after chemoradiation treatment.

Using liquid biopsies to test for ESR1 mutations in breast cancer is more feasible for patients and has quicker turnaround times.

Practicing at top of licensure can create opportunities for oncology APPs to engage with patients and other providers in new ways.

Working with patients in new contexts can provide meaning for oncology PAs, potentially reducing burnout, according to Eric Tetzlaff, MHS, PA-C, DFAAPA.

Rates of pay, bonus pay, and changes to funding for continuing education were not significantly linked with burnout rates.

Restaging cancer can be an unfamiliar space, but with more experience, APPs can rely less on MDs for guidance in such cases.

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.

Erica S. Doubleday, MS, FNP-C, BSN, RN, discussed taking advantage of available resources to provide comprehensive care for patients with breast cancer.

Katy Beckermann, MD, PhD, explained that oncology nurses and APPs should be ready to administer and explain dose modifications for patients with RCC.

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.

La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Oncology nurses can provide patients with information regarding the risks and benefits of these medications in cancer treatment.

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion center.

An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.

Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for those with advanced, treatment-naïve disease.

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.